Ischemia-Modified Albumin Levels in Essential Thrombocytosis
Yıl: 2018 Cilt: 10 Sayı: 3 Sayfa Aralığı: 341 - 346 Metin Dili: İngilizce DOI: 10.18521/ktd.376723 İndeks Tarihi: 26-02-2020
Ischemia-Modified Albumin Levels in Essential Thrombocytosis
Öz: Objective: The aim of this study was to investigate the levels of ischemia-modifiedalbumin (IMA) in people with essential thrombocytosis (ET).Methods: A total of 30 patients with ET patient group and 30 volunteers with noknown disease control group (C group) were included in this study after the approvalof ethics committee and written informed consent was obtained. Patients with a historyof major thrombosis were excluded. IMA levels and independent variables wereinvestigated and effects on thrombosis susceptibility were also studied. In addition tothat; comorbid disease state, drug use and used drugs group were questioned in patientgroup and effects of them on IMA levels were studied.Results: In our study, when ET patient group and C group were compared, the meanserum IMA levels in ET patient group and C group was detected as 0,6726 (0,527-0,776) Absorbans Unite (ABSU) and 0,4342 (0,346-0,612) ABSU respectively and inET patient group was significantly higher than C group (p<0,001). The glucose, totalcholesterol and triglyceride values were significantly higher in ET patient group (p=0,026, p= 0,058, p= 0,004, respectively). There is a correlation between IMAconcentration and age (p= 0,042).Conclusions: In our study IMA levels were found significantly high in ET patientgroup, this supports increased risk of thrombosis in ET. The difference of metabolicparameters between the ET patient group and C group can be explained by insulinresistance and atherosclerosis background caused by chronic inflammation.
Anahtar Kelime: Konular:
Esansiyel Trombositozlu Hastalarda İskemi-Modifiye Albumin Düzeyleri
Öz: Amaç: Bu çalışmanın amacı, ET olan kişilerde IMA düzeylerini incelemektir. Gereç ve Yöntem: Çalışma için etik kurul onayı ve yazılı bilgilendirilmiş onam alındıktan sonra ET hastalığı olan 30 kişi ve bilinen herhangi bir hastalığı olmayan 30 gönüllü çalışmaya dahil edildi. Majör tromboz öyküsü olan hastalar çalışma dışı bırakıldı. Çalışmada IMA düzeyleri ile bağımsız değişkenler ve tromboz duyarlılığı arasındaki ilişki değerlendirildi. Ayrıca, hasta grubunda komorbidite, ilaç kullanımı ve kullanılan ilaç grubu sorgulanarak bunların IMA düzeylerine etkisi incelendi. Bulgular: Çalışmamızda ET hasta grubu ve C grubu karşılaştırıldığında, ET hasta grubu ve C grubunda ortalama serum IMA düzeyleri sırasıyla 0,6726 (0,527-0,776) ABSU ve 0,4342 (0,346-0,612) ABSU olarak saptandı ve ET hasta grubunda C grubundan anlamlı derecede yüksekti (p <0,001). Glukoz, total kolesterol ve trigliserit değerleri ET hasta grubunda anlamlı olarak daha yüksek bulundu (sırasıyla p=0,026, p=0,058, p=0,004). IMA konsantrasyonu ile yaş değişkeni arasında anlamlı bir korelasyon saptandı (p=0,042). Sonuç: Çalışmamızda ET hasta grubunda IMA düzeyleri istatistikel düzeyde anlamlı olarak yüksek bulundu, bu da ET' de artmış tromboz riskini desteklemektedir. ET hasta grubu ve C grubu arasındaki metabolik parametrelerin farkı, kronik inflamasyonun neden olduğu insülin direnci ve ateroskleroz arka planı ile açıklanabilir.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index?: a metaanalysis of clinical outcomes in essential thrombocythemia. Leukemia research. 2009 Jan 1;33(1):67-73. Doi: 10.1016/j.leukres.2008.06.006.
- Patriarca A, Pompetti F, Malizia R, et al. Is the absence of JAK2V617F mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients. Blood Transfusion. 2010 Jan;8(1):21.Doi: 10.2450/2009.0004-09.
- detto Loria JR, Rawluk J, Krauss T, et al. Acute Transmural Myocardial Infarction by Coronary Embolism in a Patient with JAK2 V617F-Positive Essential Thrombocythemia. Hämostaseologie. 2018 May;38(02):106- 11. Doi: 10.5482/HAMO-16-12-0046.
- Palandri F, Ottaviani E, Salmi F, et al. JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leukemia & lymphoma. 2009 Jan 1;50(2):247-53.Doi: 10.1080/10428190802688152.
- Geyer H, Scherber R, Kosiorek H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. Journal of Clinical Oncology. 2015 Nov 23;34(2):151-9. Doi: 10.1200/JCO.2015.62.9337.
- Tefferi A. Essential thrombocythemia and thrombocytosis. In: Greer JP, Foerster J, Rodgers GM, Glader B, Arber DA, Means RT, eds. Wintrobe's clinical hematology 12th ed. Philadelphia; Lippincott Williams and Wilkins, 2009; 1352-60.
- Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007 Feb;21(2):270-6. Doi: 10.1038/sj.leu.2404500.
- Landolfi R, Marchioli R, Kutti Jet al. Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine. 2004 Jan 8;350(2):114-24.Doi: 10.1056/NEJMoa035572.
- Ozdem S, Cete Y, Donmez L, et al. Serum levels of ischemia-modified albumin (IMA) in healthy adults and patients with acute coronary syndrome. Turk J Emerg Med. 2005;5:169-74.
- Mojibi N, Bagheri B, Zargari M. The Clinical Evaluation Role of Ischaemia Modified Albumin in Diagnosis of Acute Coronary Syndrome: Unstable Angina to Myocardial Infarction. Journal of Clinical & Diagnostic Research. 2018 Jan 1;12(1):6-9.
- Turedi S, Patan T, Gunduz A, et al. Ischemia-modified albumin in the diagnosis of pulmonary embolism: an experimental study. The American journal of emergency medicine. 2009 Jul 1;27(6):635-40. Doi: 10.1016/j.ajem.2008.05.002.
- Ma SG, Jin Y, Hu W, et al. Evaluation of ischemia-modified albumin and C-reactive protein in type 2 diabetics with and without ketosis. Biomarker insights. 2012 Jan;7:19-26. Doi: 10.4137/BMI.S9060.
- Bar-Or D, Curtis G, Rao N, et al. Characterization of the Co2+ and Ni2+ binding amino-acid residues of the N-terminus of human albumin: An insight into the mechanism of a new assay for myocardial ischemia. European Journal of Biochemistry. 2001 Jan;268(1):42-8. Doi: 10.1046/j.1432-1327.2001.01846.x.
- Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008 Nov 1;93(11):1645-51. Doi:10.3324/haematol.13346.
- Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings. 2006; 81(2): 159-66. Doi: 10.4065/81.2.159.
- Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes–review and clinical implications. Clinical Chemistry and Laboratory Medicine. 2011 Feb 1;49(2):177-84. Doi: 10.1515/CCLM.2011.037.
- Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. The American journal of cardiology. 2005 Dec 1;96(11):1576-8. Doi: 10.1016/j.amjcard.2005.07.068.
- Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25(1):4-7. Doi: 10.1016/j.it.2003.10.013.
- Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica. 2011; 96(2):183-6. Doi:10.3324/haematol.2010.038299.
- Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2010; 95:xxx doi:10.3324/haematol.2010.031070.
- Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arteriosclerosis, thrombosis, and vascular biology. 2005 Apr 1;25(4):658-70.
- Barbui T, Carobbio A, Rambaldi A, et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood. 2009 Jul 23;114(4):759-63. Doi: 10.1182/blood-2009-02-206797.
- Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011 Jan 1:blood-2011. Doi: 10.1182/blood-2011-02-339002.
| APA | ERSOY E, SOYALTIN U, Peker A, Çolak A, CEYLAN C, akar h (2018). Ischemia-Modified Albumin Levels in Essential Thrombocytosis. , 341 - 346. 10.18521/ktd.376723 |
| Chicago | ERSOY Ercan,SOYALTIN UTKU ERDEM,Peker Ahmet,Çolak Ayfer,CEYLAN CENGIZ,akar harun Ischemia-Modified Albumin Levels in Essential Thrombocytosis. (2018): 341 - 346. 10.18521/ktd.376723 |
| MLA | ERSOY Ercan,SOYALTIN UTKU ERDEM,Peker Ahmet,Çolak Ayfer,CEYLAN CENGIZ,akar harun Ischemia-Modified Albumin Levels in Essential Thrombocytosis. , 2018, ss.341 - 346. 10.18521/ktd.376723 |
| AMA | ERSOY E,SOYALTIN U,Peker A,Çolak A,CEYLAN C,akar h Ischemia-Modified Albumin Levels in Essential Thrombocytosis. . 2018; 341 - 346. 10.18521/ktd.376723 |
| Vancouver | ERSOY E,SOYALTIN U,Peker A,Çolak A,CEYLAN C,akar h Ischemia-Modified Albumin Levels in Essential Thrombocytosis. . 2018; 341 - 346. 10.18521/ktd.376723 |
| IEEE | ERSOY E,SOYALTIN U,Peker A,Çolak A,CEYLAN C,akar h "Ischemia-Modified Albumin Levels in Essential Thrombocytosis." , ss.341 - 346, 2018. 10.18521/ktd.376723 |
| ISNAD | ERSOY, Ercan vd. "Ischemia-Modified Albumin Levels in Essential Thrombocytosis". (2018), 341-346. https://doi.org/10.18521/ktd.376723 |
| APA | ERSOY E, SOYALTIN U, Peker A, Çolak A, CEYLAN C, akar h (2018). Ischemia-Modified Albumin Levels in Essential Thrombocytosis. KONURALP TIP DERGİSİ, 10(3), 341 - 346. 10.18521/ktd.376723 |
| Chicago | ERSOY Ercan,SOYALTIN UTKU ERDEM,Peker Ahmet,Çolak Ayfer,CEYLAN CENGIZ,akar harun Ischemia-Modified Albumin Levels in Essential Thrombocytosis. KONURALP TIP DERGİSİ 10, no.3 (2018): 341 - 346. 10.18521/ktd.376723 |
| MLA | ERSOY Ercan,SOYALTIN UTKU ERDEM,Peker Ahmet,Çolak Ayfer,CEYLAN CENGIZ,akar harun Ischemia-Modified Albumin Levels in Essential Thrombocytosis. KONURALP TIP DERGİSİ, vol.10, no.3, 2018, ss.341 - 346. 10.18521/ktd.376723 |
| AMA | ERSOY E,SOYALTIN U,Peker A,Çolak A,CEYLAN C,akar h Ischemia-Modified Albumin Levels in Essential Thrombocytosis. KONURALP TIP DERGİSİ. 2018; 10(3): 341 - 346. 10.18521/ktd.376723 |
| Vancouver | ERSOY E,SOYALTIN U,Peker A,Çolak A,CEYLAN C,akar h Ischemia-Modified Albumin Levels in Essential Thrombocytosis. KONURALP TIP DERGİSİ. 2018; 10(3): 341 - 346. 10.18521/ktd.376723 |
| IEEE | ERSOY E,SOYALTIN U,Peker A,Çolak A,CEYLAN C,akar h "Ischemia-Modified Albumin Levels in Essential Thrombocytosis." KONURALP TIP DERGİSİ, 10, ss.341 - 346, 2018. 10.18521/ktd.376723 |
| ISNAD | ERSOY, Ercan vd. "Ischemia-Modified Albumin Levels in Essential Thrombocytosis". KONURALP TIP DERGİSİ 10/3 (2018), 341-346. https://doi.org/10.18521/ktd.376723 |
